Commercial Licenses a. Perpetual Named-User – Unlimited-Use, Single-Machine License: This license is locked to a particular physical machine and its use is restricted to a single identified person. That person is allowed an unlimited number of simultaneous uses.
Commercial Licenses. Subject to payment by COMPANY of the amounts provided for below and COMPANY’s compliance with the other terms and conditions of this Agreement, SELEXIS hereby grants to COMPANY a non-exclusive license under the SELEXIS Patent Rights and SELEXIS Know-How, in the Territory, with the limited right to sublicense in accordance with Article 2.2, to use (and have used only by permitted Sublicensees in accordance with Sections 2.2 and 2.3) Company-Specific Cell Lines and SELEXIS Materials for the manufacture of Licensed and/or Final Products in the Licensed Field of Use and to make, have made, use, offer for sale, sell, import and otherwise exploit Licensed and/or Final Products, including, without limitation, the use of Licensed and Final Products in Clinical Trials (the “Commercial License”).
Commercial Licenses. Selexis hereby grants to COMPANY and its Affiliates a non-exclusive license (“Commercial License”) in the Territory, with the right to sublicense as per Section 2.2 hereafter, under the Selexis Technology, subject to the terms and conditions of the Agreement, to use Cell Lines for the manufacture of Products in the Licensed Field of Use, either at Company facilities or Contractors (subject to Sections 2.1 and 2.2), and to make, have made, use, offer for sale, sell, import, export and otherwise exploit Products, including, without limitation, the use of Products in Clinical Trials.
Commercial Licenses. Upon the COMPANY exercising the Commercial License Option as provided in the Services Agreement, Selexis hereby grants to COMPANY and its Affiliates a [ ** ], including the right to sublicense as per clause 2.1.1 hereafter, [ ** ].
Commercial Licenses. (a) Subject to the terms and conditions of this Agreement, Evogene, on behalf of itself and its Affiliates, grants and agrees to grant to Monsanto and its Affiliates (in each case, so long as such Person remains an Affiliate of Monsanto), and Monsanto hereby accepts for itself and its Affiliates, an exclusive, irrevocable (except pursuant to termination or forfeiture as elsewhere set forth herein), non-transferable (except to pursuant to Section 17.5), perpetual (subject to fulfillment of the Monsanto Diligence Obligations set forth in Sections 5.10.1, 5.10.2, 5.10.3, and 5.10.4 and unless otherwise terminated in accordance with the terms hereof), royalty-bearing, worldwide license (with the right to sublicense and permit further sublicenses subject to Section 3.3), under the Evogene Patent Rights and Evogene Know-How, to (i) Commercially Exploit Collaboration Hits, their respective Collaboration Hit Homologs and Special Collaboration Hits, in all fields of use, and (ii) Commercially Exploit PlaNet Xxxx Xxxxxx and RePack Recommendations, but in the case of both (i) and (ii) solely for transgenic applications in the Monsanto Crops, and in the case of (ii), solely in connection with any Collaboration Hit Homolog belonging to the specific Collaboration Hit Set containing the specific Collaboration Hit Homolog for which Evogene delivered the Preferred Mode of Use which contained such PlaNet Xxxx Xxxxx or RePack Recommendation, as the case may be (the “Commercial License”).
Commercial Licenses. In the event that Principal Investigator and/or Licensee becomes aware of a potential third party commercial licensee for the DNA Sequences Licensee shall inform Licensor in writing of all details.
Commercial Licenses. (a) Subject to the terms and conditions of this Agreement, MAXYGEN agrees to grant, and hereby grants, to PIONEER, worldwide, royalty- bearing licenses, with the right to sublicense as set forth in (P)3.1(B)(b) below, under MAXYGEN's interest in the Intellectual Property (whether solely or jointly owned by MAXYGEN) as follows:
Commercial Licenses. Upon the effectiveness of a Participation Waiver as set forth in Sections 3.3 or 3.4(b), the Non-Participating Party shall grant to the Participating Party an exclusive, worldwide license, with rights to sub-license, under the Non-Participating Party's interests in the Research Information and Joint Patents, to make, use, and sell the particular Collaboration Product or Other Product subject to such Participation Waiver.
Commercial Licenses. Effective upon the designation of each of the […***…] Licensed-to-MedImmune Proteins as such under Section 2.1(c), Xencor hereby grants to MedImmune a worldwide, exclusive, […***…] under the Xencor Patents in all fields in the Territory, to research, have researched, develop, have developed, make, have made, use, have used, sell, have sold, offer to sell, import and/or export such Licensed-to-MedImmune Protein and the Licensed-to-MedImmune Products that contain it. Such license grant may become effective as to a […***…] Licensed-to-MedImmune Proteins only.
Commercial Licenses. The Borough agrees to pay for all commercial licenses needed by employees to perform their jobs.
